1-methyl-2-(4-benzoyl)imidazolecarboxylate | 166332-53-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-methyl-2-(4-benzoyl)imidazolecarboxylate
• 英文别名: 1H-Imidazole-5-carboxylic acid, 2-benzoyl-1-methyl-, methyl ester；methyl 2-benzoyl-3-methylimidazole-4-carboxylate
• CAS: 166332-53-2
• 化学式: C₁₃H₁₂N₂O₃
• 分子量: 244.25
• InChiKey: UTWZFEXPWHNSNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methyl-2-(4-benzoyl)imidazolecarboxylate 在 硫酸 作用下， 反应 3.0h， 以77%的产率得到1-methyl-2-(4-benzoyl)imidazole-5-carboxylic acid
  参考文献：
  名称：

  Synthesis and antiinflammatory—analgesic profile of 1-methyl-2-(4-X-benzoyl) imidazole-5-carboxylic acids

  摘要：

  A set of 1-methyl-2-(4-X-benzoyl)imidazole-5-carboxylic acids, designed as antiinflammatory-analgesic agents, were synthesized and biologically evaluated in vivo (writhing test and the carrageenen rat pleurisy) using tolmetin as a reference drug. The compounds were also tested in vitro on the cyclooxygenase enzyme of sheep vescicular microsome. Distribution coefficients In the octanol-buffer system at different pH values have been determined for their potential influence on activity. Although the investigated compounds exhibited moderate or no inhibitory activity against cyclooxygenase in in vitro and in vivo assays, two of them (the 4-nitrobenzoyl and the 4-chlorobenzoyl derivatives 1e and 1b) were found to be more active than tolmetin in the writhing test. Moreover, 1b also showed higher activity in the pleurisy assay.

  DOI：

  10.1016/0223-5234(96)88239-0
• 作为产物：
  描述：

  1-甲基咪唑-5-甲酸甲酯 以61%的产率得到
  参考文献：
  名称：

  Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., +, Eur. J. Med. Chem., 30 (1995) N 4, S 315-320

  摘要：

  DOI：

文献信息

• HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Wrobleski Stephen T.

  公开号：US20080171741A1

  公开（公告）日：2008-07-17

  A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.

  公式I的化合物及其对映体、非对映异构体和药学上可接受的盐。还披露了含有公式I化合物的药物组合物，以及治疗与p38激酶活性相关的疾病的方法。
• Heterocyclic Amide Compounds Useful as Kinase Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：EP2468717A1

  公开（公告）日：2012-06-27

  A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.

  式 I 的化合物 及其对映体、非对映体和药学上可接受的盐。还公开了含有式 I 化合物的药物组合物，以及治疗与 p38 激酶活性相关的病症的方法。
• WO2008/57775
  申请人：——

  公开号：——

  公开（公告）日：——
• Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., +, Eur. J. Med. Chem., 30 (1995) N 4, S 315-320
  作者：Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., +

  DOI：——

  日期：——
• US7935696B2
  申请人：——

  公开号：US7935696B2

  公开（公告）日：2011-05-03